| Funding Opportunity ID: |
329898 |
| Opportunity Number: |
RFA-MH-21-106 |
| Opportunity Title: |
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) |
| Opportunity Category: |
Discretionary |
| Opportunity Category Explanation: |
|
| Funding Instrument Type: |
Grant |
| Category of Funding Activity: |
Health |
| Category Explanation: |
|
| CFDA Number(s): |
93.242
93.313 |
| Eligible Applicants: |
State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: |
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
| Agency Code: |
HHS-NIH11 |
| Agency Name: |
Department of Health and Human Services
National Institutes of Health |
| Posted Date: |
Nov 18, 2020 |
| Close Date: |
Feb 09, 2021 |
| Last Updated Date: |
Nov 18, 2020 |
| Award Ceiling: |
$0 |
| Award Floor: |
$0 |
| Estimated Total Program Funding: |
|
| Expected Number of Awards: |
|
| Description: |
The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work. |
| Version: |
1 |
